Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs

Journal of Clinical Psychiatry

Volumn 60, Issue 5, 1999, Pages 326-335

  Hirschfeld, Robert M A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; HEADACHE; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MELANCHOLIA; NAUSEA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032994963     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0511     Document Type: Article

References (58)

1. Hirschfeld RMA, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997;277:333-340
2. Bielski RJ, Friedel RO. Prediction of tricyclic antidepressant response: a critical review. Arch Gen Psychiatry 1976;33:1479-1489
3. Kocsis JH, Croughan JL, Katz MM, et al. Response to treatment with anti-depressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry 1990;147: 621-624
4. Nelson JC, Mazure CM, Jatlow PI. Does melancholia predict response in major depression? J Affect Disord 1990;18:157-165
5. Peselow ED, Sanfilipo MP, Difiglia C, et al. Melancholic/endogenous depression and response to somatic treatment and placebo. Am J Psychiatry 1992;149:1324-1334
6. Rush AJ, Weissenburger JE. Melancholic symptom features and DSM-IV. Am J Psychiatry 1994;151:489-498
7. Zimmerman M, Spitzer RL. Melancholia: from DSM-III to DSM-III-R. Am J Psychiatry 1989;146:20-28
8. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
9. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-138
10. Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151:1735-1739
11. Prien RF, Carpenter LL, Kupfer DJ. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 1991;48:796-800
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), Fourth Edition. Washington, DC: American Psychiatric Association; 1994
13. Nierenberg AA. The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? J Clin Psychiatry 1994;55(9, suppl A):55-59
14. Angst J, Delini-Stula A, Stabl M, et al. Is a cut-off score a suitable measure of treatment outcome in short-term trials in depression? a methodological meta-analysis. Hum Psychopharmacol 1993;8:311-317
15. Ottevanger EA. Fluvoxamine and clomipramine in depressed hospitalized patients: results from a randomized, double-blind study. Encephale 1995; 21:317-321
16. Arminen S-L, Ikonen U, Pulkkinen P, et al. A 12-week, double-blind, multicentre study of paroxetine and imipramine in hospitalized depressed patients. Acta Psychiatr Scand 1994;89:382-389
17. Beasley CM Jr, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression: a multicenter trial. Ann Clin Psychiatry 1993;5:199-208
18. Bowden CL, Schatzberg AF, Rosenbaum A, et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 1993;13: 305-311
19. Lader M. Fluoxetine efficacy vs comparative drugs: an overview. Br J Psychiatry 1988;153(suppl 3):51-58
20. Tignol J, Stoker MJ, Dunbar GC. Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 1992;7:91-94
21. Ginestet D. Fluoxetine in endogenous depression and melancholia versus clomipramine. Int Clin Psychopharmacol 1989;4(suppl 1):37-40
22. Fabre LF, Brodie HK, Garver D, et al. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J Clin Psychiatry 1983;44(5 pt 2):88-94
23. Merideth CH, Feighner JP. The use of bupropion in hospitalized depressed patients. J Clin Psychiatry 1983;44(5 pt 2):85-87
24. Feighner J, Targum SD, Bennett ME, et al. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. J Clin Psychiatry 1998;59:246-253
25. Clerc GE, Ruimy P, Verdeau-Paillès J, for the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143
26. Wheatley D, Kremer C. A randomized, double-blind comparison of mirtazapine and fluoxetine in patients with major depression. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 20, 1997; San Diego, Calif. Abstract NR208:124
27. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995;56:519-525
28. Kasper S, Möller H-J, Montgomery SA, et al. Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. Int Clin Psychopharmacol 1995;9 (suppl 4):3-12
29. Pande AC, Sayler ME. Severity of depression and response to fluoxetine. Int Clin Psychopharmacol 1993;8:243-245
30. Feighner JP, Cohn JB, Fabre LF Jr, et al. A study comparing paroxetine, placebo, and imipramine in depressed patients. J Affect Disord 1993;28: 71-79
31. Reimherr FW, Byerley WF, Ward MF, et al. Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder. Psychopharmacol Bull 1988;24:200-205
32. Vestergaard P, Gram LF, Kragh-Sørensen P, et al., and the Danish University Antidepressant Group. Therapeutic potentials of recently introduced antidepressants. Psychopharmacol Ser 1993;10:190-198
33. Wheadon DE, Bushnell WD, Pitts CD, et al. Effect of response criteria, severity of illness, and duration of illness on placebo response in trial of two serotonin reuptake inhibitors. Presented at the 31st annual meeting of the American College of Neuropsychopharmacology; December 1992; San Juan, Puerto Rico
34. Doogan DP, Langdon CJ. A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 1994;9:95-100
35. Heiligenstein JH, Tollefson GD, Faries DE. Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo. J Affect Disord 1994;30: 163-173
36. Stuppaeck CH, Geretsegger C, Whitworth AB, et al. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 1994;14:241-246
37. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992;53(2, suppl):21-26
38. 38. Feighner JP, Boyer WF, Meredith CH, et al. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 1989;4:239-244
39. Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry 1991;48:1075-1081
40. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985;142:430-436
41. Rothschild AJ, Samson JA, Bessette MP, et al. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993;54:338-342
42. Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry 1990;147:1203-1208
43. Miller FT, Freilicher J. Comparison of TCAs and SSRIs in the treatment of major depression in hospitalized geriatric patients. J Geriatr Psychiatry Neurol 1995;8:173-176
44. Guillibert E, Pelicier Y, Archambault JP, et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand 1989;80(suppl 350):132-134
45. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458
46. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997; 17:10-21
47. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996;57(suppl 2):46-52
48. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57 (suppl 2):53-62
49. Ascher JA, Cole JO, Colin J-N, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56:395-401
50. Nelson JC, Mazure CM, Bowers MB Jr, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
51. Nierenberg AA, Cole JO, Glass L. Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry 1992;53:83-85
52. Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989;50:447-449
53. Zajecka JM, Jeffriess H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry 1995;56:338-343
54. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320
55. Sackeim HA, Rush AJ. Melancholia and response to ECT [letter]. Am J Psychiatry 1995;152:1242-1243
56. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res 1990;31:287-296
57. American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993;150(suppl 4):1-26
58. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2. Treatment of Major Depression. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551